公开(公告)号：US12208059B2

公开(公告)日：2025-01-28

申请号：US17435443

申请日：2020-03-03

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE —HÔPITAUX DE PARIS ,  UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE

Inventor： Guillaume Carteaux ,  Armand Mekontso Dessap

IPC: A61H31/02 ,  A61H31/00

Abstract: The invention relates to a device (10) for selective regionalization of pulmonary aeration, intended to apply a vacuum over a posterolateral part of a patient's chest wall, said device comprising a rigid or semi-rigid shell (11) intended to selectively surround a posterior part of the patient's chest wall, and a layer of honeycomb material (12) covering an internal wall (13) of the rigid shell, intended to be in contact with the patient's chest wall, said shell comprising at least one through hole (14), intended to be connected to a negative pressure generator.

公开(公告)号：US20250011792A1

公开(公告)日：2025-01-09

申请号：US18709695

申请日：2022-11-30

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  FONDATION IMAGINE ,  UNIVERSITÉ PARIS CITÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Olivier HERMINE ,  Mirjana WEIMERSHAUS ,  Thiago TROVATI MACIEL ,  Peter VAN ENDERT ,  Michael DUSSIOT ,  Rachel RIGNAULT-BRICARD ,  Caroline CARVALHO

IPC: C12N15/113 ,  A61K31/351 ,  A61K31/381 ,  A61K31/4433 ,  A61K31/4709 ,  A61K38/07 ,  A61K38/12

Abstract: Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors and other inflammatory molecules via the constitutive pathway that remains ill-defined. Here the inventors describe a role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-α and IL-6 in mast cells and macrophages. IRAP-deficient mice are protected from TNF-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF fails to be efficiently exported from the Golgi. Chemical targeting of IRAP+ endosomes reduced pro-inflammatory cytokine secretion thereby highlighting this compartment as a promising target for the therapeutic control of inflammation. Thus the present invention relates to the use of IRAP inhibitors for the treatment of inflammatory diseases

公开(公告)号：US20240371526A1

公开(公告)日：2024-11-07

申请号：US18688493

申请日：2022-09-02

Applicant: ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  SORBONNE UNIVERSITÉ

Inventor： Aurélie HANIN ,  Vincent NAVARRO ,  Mario CHAVEZ ,  Sophie DEMERET

IPC: G16H50/30 ,  G01N33/68 ,  G16H10/60 ,  G16H20/10

Abstract: The invention relates to the field of patient's care and describes method and systems, for prediction of mortality, functional outcome and recovery after status epilepticus, based on machine classifiers and logistic regression functions, and using biological markers and variables easily obtainable in intensive care units.

公开(公告)号：US20240132964A1

公开(公告)日：2024-04-25

申请号：US18546611

申请日：2022-02-16

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ PARIS CITÉ ,  FONDATION IMAGINE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

Inventor： Mickaël MENAGER ,  Julie TOUBIANA ,  Darragh DUFFY ,  Frédéric LAUCAT

IPC: C12Q1/6883

CPC classification number: C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: SARS-CoV-2 infection in children is generally milder than in adults, yet a proportion of cases result in hyperinflammatory conditions often including myocarditis. To better understand these cases, the inventors applied a multi-parametric approach to the study of blood cells of 56 children hospitalized with suspicion of SARS-CoV-2 infection. The most severe forms of MIS-C (multisystem inflammatory syndrome in children related to SARS-CoV-2), that resulted in myocarditis, were characterized by elevated levels of pro-angiogenesis cytokines and several chemokines. This phenotype was associated with TNF-α signaling, sustained NF-κB signaling in monocytic/dendritic cells, alongside increased HIF-1α and VEGF signaling. Single-cell transcriptomic analyses identified

公开(公告)号：US20240075063A1

公开(公告)日：2024-03-07

申请号：US18256788

申请日：2021-12-09

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE PARIS ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS

Inventor： Sophie CAILLAT-ZUCMAN ,  Nana TALVARD-BALLAND

IPC: A61K35/17 ,  A61P35/02

CPC classification number: A61K35/17 ,  A61P35/02 ,  A61K2035/124

Abstract: The inventors explored in an allogeneic situation the regulatory potential of Mucosal-Associated Invariant T cells (MAIT cells), a population of unconventional T cells that exhibit potent antibacterial activity, expressing a semi-invariant TCR which recognizes vitamin B2 derivatives of microbial origin presented by the MR1 molecule. In particular, the inventors used i) an allogenic reaction model in vitro (mixed lymphocyte reaction, MLR) and ii) murine model of xenogeneic aGvHD They first verified that human MAIT cells do not proliferate in response to allogeneic stimulation in vitro (MLR) or in vivo (immunodeficient mice) alone but require for their expansion both an inflammatory environment and TCR ligation by its ligand. In contrast, MAIT cells are able to inhibit the proliferation of allospecific LT in vitro in a dose-dependent manner. Furthermore, the adoptive transfer of MAIT cells in a mouse model of xeno-GVHD resulted in a delay in early or late GvHD development. Altogether, these data describe a new regulatory function of MAIT cells in an allogeneic context, allowing us to consider their use in cell therapy to limit GvHD.

公开(公告)号：US20230390309A1

公开(公告)日：2023-12-07

申请号：US18031632

申请日：2021-10-14

Applicant: INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  SORBONNE UNIVERSITE ,  UNIVERSITE PARIS-SACLAY

Inventor： BRUNO FIGADERE ,  RITA RAISMAN-VOZARI ,  PATRICK PIERRE MICHEL ,  LAURENT FERRIE ,  CLÉMENCE ROSE

IPC: A61K31/65 ,  C07C231/12 ,  C07C235/84 ,  A61P25/28

CPC classification number: A61K31/65 ,  C07C231/12 ,  C07C235/84 ,  A61P25/28 ,  C07C2603/46

Abstract: The present invention relates to the field of medicine. In particular, it relates to the use of tetracycline derivatives in the treatment or prevention of a neurodegenerative or neuroinflammatory disease, such as Parkinson's disease.

公开(公告)号：US20230365936A1

公开(公告)日：2023-11-16

申请号：US18319224

申请日：2023-05-17

Applicant: FUJIFILM Corporation ,  Assistance Publique - Hôpitaux de Paris

Inventor： Nisa K. E. RENAULT ,  Michele L. Hamrick ,  Chad H. Koonce ,  Philippe Menasche ,  Valerie Bellamy ,  Camille Humbert ,  Guillaume Churlaud ,  Jerome Larghero

IPC: C12N5/0775 ,  C12N5/00 ,  A61P9/10

CPC classification number: C12N5/0662 ,  C12N5/0031 ,  A61P9/10 ,  C12N2501/998 ,  C12N2501/115

Abstract: The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesicles, and fractions thereof. The present disclosure further provides methods for analyzing activities, and the functionality and potency, of such secretomes, extracellular vesicles, and fractions thereof. The present disclosure also relates to the therapeutic use of secretomes, extracellular vesicles, and fractions thereof. The present disclosure further relates to a good manufacturing practices (GMP)-ready, scalable, culture protocol for the release of clinic-ready secretomes.

公开(公告)号：US20230293577A1

公开(公告)日：2023-09-21

申请号：US18042187

申请日：2021-08-19

Applicant: ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  UNIVERSITÉ PARIS CITÉ

Inventor： Hang Korng EA ,  Vincent BOUDY ,  Amélie WOJCICKI ,  Sophie DUFAY

IPC: A61K33/04 ,  A61K9/06 ,  A61K47/36 ,  A61K31/198 ,  A61K31/19 ,  A61K31/194 ,  A61K33/42 ,  A61K33/06 ,  A61K38/17 ,  A61K38/46 ,  A61K38/19 ,  A61P3/14

CPC classification number: A61K33/04 ,  A61K9/06 ,  A61K31/19 ,  A61K31/194 ,  A61K31/198 ,  A61K33/06 ,  A61K33/42 ,  A61K38/1709 ,  A61K38/19 ,  A61K38/465 ,  A61K47/36 ,  A61P3/14

Abstract: The invention concerns an alginate hydrogel or a new composition derived therefrom further comprising another calcium chelator such as sodium thiosulfate and/or calcium crystal solubilizer or inhibitor, and their use in the treatment of ectopic calcifications or disorders comprising ectopic calcifications.

公开(公告)号：US20230279438A1

公开(公告)日：2023-09-07

申请号：US17998603

申请日：2021-05-12

Applicant: INSERM (Institut National de la Santé et la Recherche Médicale) ,  Université Paris Cité ,  Assistance Publique-Hôpitaux de Paris ,  Fondation Imagine

Inventor： Annarita MICCIO ,  Panagiotis ANTONIOU ,  Marina CAVAZZANA

IPC: C12N15/90 ,  C12N9/78 ,  C12N9/22 ,  C12N15/11

CPC classification number: C12N15/90 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11 ,  C12Y305/04005 ,  C12N2310/20 ,  C12N2320/34

Abstract: The clinical history of β-hemoglobinopathies shows that the severity is mitigated by the synthesis of the fetal γ-globin in adulthood, typically associated with genetic variants the HBB cluster known as hereditary persistence of fetal hemoglobin (HPFH) mutations. The inventors identified that most of the known HPFH mutations in the γ-globin promoters (C>T, G>A, T>C or A>G) can be recapitulated using CBE- and ABE-mediatedbase-editing approaches. In particular, the inventors designed gRNAs that, when combined with CBEs or ABEs, generate HPFH mutations, and either disrupt binding sites for transcriptional repressors (-200 and -115 sites) or generate de novo DNA motifs recognized by transcriptional activators (e.g., -198 T>C, the -175 T>C and -113 A>G). It is noteworthy that a subset of the gRNAs targeting the -200 and the 115 regions are predicted to generate simultaneously HPFH mutations and also to make base changes other than HPFH mutations in or around the LRF and BCL11A binding sites, which might further reduce LRF and BCL11A occupancy. Accordingly, the present invention relates to base editing approaches for the treatment of β-hemoglobinopathies.

公开(公告)号：US20230266322A1

公开(公告)日：2023-08-24

申请号：US18003999

申请日：2021-06-28

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  SORBONNE UNIVERSITÉ ,  Université Paris Cité

Inventor： Franck PAGES ,  Jérôme GALON ,  Guy ZEITOUN ,  Amos KIRILOVSKY

IPC: G01N33/574

CPC classification number: G01N33/574 ,  G01N2800/54

Abstract: The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to a postoperative adjuvant therapy. The inventors showed that ISB was an independent parameter, more informative than pre- (P